Cencora, Inc. $COR Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue raised its stake in Cencora, Inc. (NYSE:COR) by 5.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,177 shares of the company’s stock after buying an additional 1,810 shares during the period. State of Alaska Department of Revenue’s holdings in Cencora were worth $11,618,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of COR. Vanguard Group Inc. grew its holdings in shares of Cencora by 5.3% in the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after acquiring an additional 1,125,661 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cencora by 6.3% during the second quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after purchasing an additional 284,229 shares during the last quarter. Norges Bank acquired a new position in shares of Cencora in the 2nd quarter valued at $695,215,000. Viking Global Investors LP boosted its position in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after purchasing an additional 1,013,913 shares during the period. Finally, Amundi increased its stake in Cencora by 17.0% in the 2nd quarter. Amundi now owns 1,720,278 shares of the company’s stock worth $500,893,000 after purchasing an additional 249,742 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. TD Cowen upped their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Bank of America dropped their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research report on Monday, January 5th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Finally, Mizuho increased their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $379.50.

Insiders Place Their Bets

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 20,317 shares of company stock valued at $7,009,260 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Cencora Price Performance

COR opened at $335.73 on Friday. The stock has a fifty day moving average price of $349.89 and a 200 day moving average price of $318.10. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 1 year low of $233.61 and a 1 year high of $377.54. The stock has a market cap of $65.13 billion, a price-to-earnings ratio of 42.23, a PEG ratio of 1.60 and a beta of 0.66.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio is presently 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.